Midatech Pharma PLC Rule 2.9 Announcement - Typo Correction (5489K)
April 22 2020 - 10:51AM
UK Regulatory
TIDMMTPH
RNS Number : 5489K
Midatech Pharma PLC
22 April 2020
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF SUCH JURISDICTION.
22 April 2020
Midatech Pharma PLC
("Midatech" or the "Company")
Rule 2.9 Announcement - Typo correction
The following amendment has been made to Midatech's 2.9
announcement that was released on the 20 April 2020 which had the
incorrect International Securities Identification Number ("ISIN")
for the Company's American Depositary Receipts ("ADRs"). The ISIN
for these ADRs is US59564R3021.
The announcement should have read:
In accordance with Rule 2.9 of the Takeover Code, Midatech
confirms that, as at the date of this announcement, it has
23,494,981 ordinary shares with par value GBP0.001 in issue
("Ordinary Shares") and admitted to trading on the AIM market of
the London Stock Exchange with International Securities
Identification Number GB00BKT14T00. The Company has an American
Depositary Receipts facility ("ADRs", where each ADR represents 5
Ordinary Shares) with 998,655 ADRs currently outstanding,
representing 4,993,275 Ordinary Shares. The ADRs are registered
with the US Securities and Exchange Commission ("SEC") and are
listed on The NASDAQ Capital Market with International Securities
Identification Number US59564R3021.
For more information, please contact:
Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)1235 888300
www.midatechpharma.com
Panmure Gordon (UK) Limited (Financial Adviser, Nominated Adviser
and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Tel: +44 (0)20 7886 2500
Noble Capital Markets, Inc. (M&A adviser)
Michel Gouy, Tel. +43 664 230 2910
Wolfgang Stoiber Tel. +1 978 697 9753
mgouy@noblelsp.com / wstoiber@noblelsp.com
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Joseph Green/ Laine Yonker
Tel: (646) 653-7030/ 7035
jgreen@edisongroup.com/ lyonker@edisongroup.com
Publication on website
A copy of this announcement will be made available (subject
to certain restrictions relating to persons resident in restricted
jurisdictions) on the Company's website at www.midatechpharma.com
in accordance with Rule 26.1 of the Code by no later than 12
noon (London time) on 21 April 2020. For the avoidance of doubt,
the content of the website referred to in this announcement
is not incorporated into and does not form part of this announcement.
Disclosure requirements of the Code
Under Rule 8.3(a) of the Code, any person who is interested
in 1% or more of any class of relevant securities of an offeree
company or of any securities exchange offeror (being any offeror
other than an offeror in respect of which it has been announced
that its offer is, or is likely to be, solely in cash) must
make an Opening Position Disclosure following the commencement
of the offer period and, if later, following the announcement
in which any securities exchange offeror is first identified.
An Opening Position Disclosure must contain details of the person's
interests and short positions in, and rights to subscribe for,
any relevant securities of each of (i) the offeree company and
(ii) any securities exchange offeror(s). An Opening Position
Disclosure by a person to whom Rule 8.3(a) applies must be made
by no later than 3.30 pm (London time) on the 10th business
day following the commencement of the offer period and, if appropriate,
by no later than 3.30 pm (London time) on the 10th business
day following the announcement in which any securities exchange
offeror is first identified. Relevant persons who deal in the
relevant securities of the offeree company or of a securities
exchange offeror prior to the deadline for making an Opening
Position Disclosure must instead make a Dealing Disclosure.
Under Rule 8.3(b) of the Code, any person who is, or becomes,
interested in 1% or more of any class of relevant securities
of the offeree company or of any securities exchange offeror
must make a Dealing Disclosure if the person deals in any relevant
securities of the offeree company or of any securities exchange
offeror. A Dealing Disclosure must contain details of the dealing
concerned and of the person's interests and short positions
in, and rights to subscribe for, any relevant securities of
each of (i) the offeree company and (ii) any securities exchange
offeror(s), save to the extent that these details have previously
been disclosed under Rule 8. A Dealing Disclosure by a person
to whom Rule 8.3(b) applies must be made by no later than 3.30
pm (London time) on the business day following the date of the
relevant dealing.
If two or more persons act together pursuant to an agreement
or understanding, whether formal or informal, to acquire or
control an interest in relevant securities of an offeree company
or a securities exchange offeror, they will be deemed to be
a single person for the purpose of Rule 8.3.
Opening Position Disclosures must also be made by the offeree
company and by any offeror and Dealing Disclosures must also
be made by the offeree company, by any offeror and by any persons
acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).
Details of the offeree and offeror companies in respect of whose
relevant securities Opening Position Disclosures and Dealing
Disclosures must be made can be found in the Disclosure Table
on the Takeover Panel's website at www.thetakeoverpanel.org.uk,
including details of the number of relevant securities in issue,
when the offer period commenced and when any offeror was first
identified. You should contact the Takeover Panel's Market Surveillance
Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether
you are required to make an Opening Position Disclosure or a
Dealing Disclosure.
Additional information
Panmure Gordon (UK) Limited ("Panmure") is authorised and regulated
by the Financial Conduct Authority in the United Kingdom. Panmure
is acting as financial adviser in relation to the Code exclusively
for M idatech and no one else in connection with the matters
set out in this announcement and will not regard any other person
as its client in relation to the matters set out in this announcement
and will not be responsible to anyone other than Midatech for
providing the protections afforded to clients of Panmure or
its affiliates, or for providing advice in relation to the contents
of this announcement or any other matter referred to herein.
Noble Capital Markets ("Noble") is a research-driven boutique
investment bank that has supported small & micro-cap companies
since 1984. As a FINRA and SEC licensed, broker-dealer Noble
provides institutional-quality equity research, merchant and
investment banking, wealth management, and order execution services.
Noble Life Science Partners, a division of Noble Capital Markets,
Inc. combines industry and scientific knowledge to provide our
clients with value-added research, advisory, licensing, M&A,
and investment and merchant banking services. The Scientific
Advisory Board (SAB) was formed for the overall objective of
being instrumental and impactful in the growth and expansion
of platform through highly focused, in-depth, and substantive
advice with regards to new discoveries, technologies, products,
services, new developments/trends in the Medical/Biotechnology/Pharmaceutical
Industry worldwide.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RTTPPUWCCUPUGCP
(END) Dow Jones Newswires
April 22, 2020 10:51 ET (14:51 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Oct 2023 to Oct 2024